Alex Biese

A vaccine for pancreatic and colorectal cancers is showing promise, but potential availability of the drug is likely several years away, an expert said.

“When you have support, you have answers to some of your unknowns and that can provide stability and ease in anxiety and depression, and truly propel you into thriving,” a cervical cancer survivor and advocate tells CURE®.

A multidose regimen of the novel human fusion protein with a treatment combination may result in prolonged survival after acute graft-versus-host-disease.

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

Findings from the ASCERTAIN trial support the use of oral Inqovi for adults with intermediate- and high-risk myelodysplastic syndromes (MDS) such as chronic myelomonocytic leukemia (CMML).

CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.

Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared with the overall population.

Researchers claim to have determined the maximum=tolerated dose and usage of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative radiotherapy boost for patients with locally advanced unresectable non-small cell lung cancer, according to recently published findings.

Dr. Dustin Deming, a gastrointestinal oncologist, began his own cancer journey more than a decade ago when he received a diagnosis of rectal cancer.

“In my career of almost 30 years, I've never seen a liver cancer patient that did not have a chronic underlying liver disease,” Dr. Mindie H. Nguyen told CURE®.

Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious side effects leading to regorafenib treatment discontinuation, researchers have found.

We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.

Antiviral treatments play a crucial role in the survival of patients with either hepatitis B or C and liver cancer, but researchers have found that antiviral therapy is “severely underutilized” even among patients who undergo curative surgery.

Patients recently treated for cancer who required hospitalization for COVID-19 were at risk for venous thromboembolisms (VTEs), recent research has found, with investigators determining that patients who experience a thromboembolic event (TEE) are at a 20% to 25% risk of death.

BTK degrader NX-5948 has been granted Fast Track designation by the FDA to treat some adults with relapsed or refractory chronic lymphocytic leukemia or relapsed or refractory small lymphocytic lymphoma.

The Food and Drug Administration (FDA) has recently approved Keytruda (pembrolizumab) plus chemoradiotherapy for the treatment of patients with stages 3 to 4A cervical cancer.

Endocrine therapy, particularly when administered in combination with Verzenio (abemaciclib), is effective when compared with chemotherapy among patients with metastatic breast cancer who experienced disease progression on Ibrance (palbociclib), according to recently published research.

From Tom Green to Deadpool, humor-based messaging has long been utilized for testicular cancer. Researchers aren’t sure how effective that strategy is.

Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.

Patients with melanoma play a vital role in their own post-surgical care, as one expert from Dana-Farber Cancer Institute explained to CURE®.

Nearly 40% of patients who received treatment for cervical cancer were still being prescribed outpatient opioids for pain management six months later, according to recently published study findings.

Award-winning journalist applied the same dedication that served her award-winning reporting in support of her own survival following a diagnosis of stage 4 anaplastic thyroid cancer.

Patients continue to be enrolled in a study evaluating the dual-action androgen receptor inhibitor ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPIs).

“When we talk about recurrence of melanoma, we actually worry more about what we cannot see, what's on the inside,” Dr. Justine V. Cohen of the Dana-Farber Cancer Institute told CURE®.

The Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) intended to convert the accelerated approval granted to Tivdak (tisotumab vedotin-tftv) in 2021 to full approval for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.

The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.

Vd1-gd T cells, a rare type of immune cell, have been found to potentially predict how likely it is that certain patients with advanced skin cancer will be responsive to treatment via immunotherapy, according to recently published research.

Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.

Researchers have found the CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) to be a cost-effective second-line treatment for patients with relapsed and refractory diffuse large B-cell lymphoma as the drug’s cost rises.